Business Context and Reporting Period
Company: ILLUMINA, INC. (ILMN)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 29, 2024 (Q3 2024)
Key Event: On June 24, 2024, Illumina completed the spin-off of GRAIL, Inc. into a separate public company. Illumina retained approximately 14.5% of GRAIL's common stock. The spin-off did not qualify as a discontinued operation.
Key Financial Metrics
| Metric (in millions) | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $1,080 | $1,119 | $3,268 | $3,382 |
| Gross Profit | $745 | $684 | $2,133 | $2,070 |
| Gross Margin | 68.9% | 61.1% | 65.3% | 61.2% |
| Net Income (Loss) | $705 | $(754) | $(1,410) | $(986) |
| Diluted EPS | $4.42 | $(4.77) | $(8.86) | $(6.23) |
| Operating Cash Flow (YTD) | $473 | $254 | $473 | $254 |
| Cash & Equivalents (End of Period) | $869 | $927 | $869 | $927 |
| Total Debt (Term Debt) | $1,988 | $1,489 | $1,988 | $1,489 |
Material Changes vs. Prior Period
- Revenue Decline: Q3 2024 revenue decreased 3% year-over-year, driven by a 41% drop in instrument revenue due to fewer shipments of high-throughput NovaSeq X instruments. Consumables revenue increased 5%.
- Profitability Surge: Q3 2024 reported a net income of $705 million compared to a net loss of $754 million in Q3 2023. This turnaround was primarily driven by a $488 million gain from the reversal of the European Commission fine related to the GRAIL acquisition.
- Impairment Charges: YTD 2024 included $1.889 billion in goodwill and intangible impairments, primarily related to GRAIL ($1.466 billion goodwill, $420 million IPR&D) recorded in Q2 2024 prior to the spin-off.
- Debt Restructuring: Illumina issued $500 million in 2026 Term Notes in September 2024 and repaid a $750 million delayed draw term loan used to fund the GRAIL spin-off.
Guidance, Outlook, and Risks
- Legal Resolution: On September 6, 2024, the European Court of Justice ruled in Illumina's favor, annulling the European Commission's jurisdiction over the GRAIL acquisition. Consequently, the EC withdrew its €432 million fine, resulting in a $481 million net gain recognized in Q3 2024.
- Remaining Litigation: While EU proceedings are resolved, Illumina faces ongoing SEC investigations, shareholder derivative lawsuits, and securities class actions regarding the GRAIL acquisition and disclosures.
- Share Repurchases: In August 2024, the Board authorized a new $1.5 billion share repurchase program. As of September 29, 2024, $1.4 billion remained available.
- Outlook: Management notes continued macroeconomic headwinds, including inflation and customer capital constraints, which may impact sales. The company expects to continue cost reduction initiatives to improve margins.
Investor Verification Checklist
- European Commission Fine Reversal: Verify the accounting treatment and tax implications of the $481 million gain from the withdrawn EC fine.
- GRAIL Investment Valuation: Review the fair value of the retained 14.5% stake in GRAIL, which incurred a $332 million unrealized loss YTD 2024.
- Contingent Consideration Liability: Monitor the $82 million liability for GRAIL contingent value rights (CVRs), which is sensitive to GRAIL's future revenue forecasts.
- Instrument Backlog: Assess the sustainability of the instrument revenue decline and the impact of the lower NovaSeq X backlog on future quarters.
- Legal Exposure: Track the status of pending SEC inquiries and shareholder derivative suits, which could result in future settlements or reputational damage.